320 related articles for article (PubMed ID: 24508002)
1. [C3 glomerulopathy].
Chauvet S; Servais A; Frémeaux-Bacchi V
Nephrol Ther; 2014 Apr; 10(2):78-85. PubMed ID: 24508002
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
3. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
4. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
5. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
[TBL] [Abstract][Full Text] [Related]
6. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
7. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
9. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
10. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
11. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL
Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143
[TBL] [Abstract][Full Text] [Related]
12. [Characteristics of pediatric C3 glomerulopathy with decreased factor H in 3 cases].
He RJ; Xiao HJ; Wang SX; Guan N; Yao Y; Ding J
Zhonghua Er Ke Za Zhi; 2012 Dec; 50(12):939-43. PubMed ID: 23324154
[TBL] [Abstract][Full Text] [Related]
13. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
14. Treatment of C3 glomerulopathy with complement blockers.
Vivarelli M; Emma F
Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
[TBL] [Abstract][Full Text] [Related]
15. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
16. The role of complement in C3 glomerulopathy.
Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
[TBL] [Abstract][Full Text] [Related]
17. A paraneoplastic membranoproliferative glomerulonephritis with isolated C3 deposits associated with hairy cell leukaemia.
Abboud I; Galicier L; De Labarthe A; Dossier A; Glotz D; Verine J
Nephrol Dial Transplant; 2010 Jun; 25(6):2026-8. PubMed ID: 20335271
[TBL] [Abstract][Full Text] [Related]
18. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.
Sethi S; Fervenza FC; Zhang Y; Zand L; Vrana JA; Nasr SH; Theis JD; Dogan A; Smith RJ
Kidney Int; 2012 Aug; 82(4):465-73. PubMed ID: 22673887
[TBL] [Abstract][Full Text] [Related]
19. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
[TBL] [Abstract][Full Text] [Related]
20. Membranoproliferative glomerulonephritis with isolated C3 deposits: case report and literature review.
Darouich S; Goucha R; Jaafoura MH; Zekri S; Kheder A; Ben Maiz H
Ultrastruct Pathol; 2011 Feb; 35(1):42-6. PubMed ID: 21265634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
